Early trials of Allocetra™, an experimental drug developed by Prof. Dror Mevorach, head of one of the COVID-19 units at Hadassah Hospital Ein Kerem, have shown great success in treating seriously ill COVID-19 patients. In the phase one and two trials, the drug had a 90 percent recovery rate. According to Prof. Mevorach, the chief scientific and medical officer at Enlivex, the maker of the drug, “it is useful for serious and critical patients because it can prevent the need to ventilate them, and that’s the major goal. Because the moment you go into ventilation, the entire situation changes, complications rise, and it’s more difficult to treat.” In phase three trials beginning now, the drug will be administered to more than 100 patients.

To read The Times of Israel article, click here.

Photo caption: Prof. Dror Mevorach, head of Hadassah Ein Kerem hospital’s coronavirus department, February 9, 2021 (Channel 13 screenshot).